Trial Profile
An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 25 Jan 2018
Price :
$35
*
At a glance
- Drugs FLX 787 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Flex Pharma
- 18 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Nov 2017 New trial record